-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Dermavant Sciences announced that the.
Vtama (1% tapinarof once daily) cream is included for all patients with psoriasis, regardless of severity, and there are no labelling restrictions on duration of use and body par.
Psoriasis, also known as psoriasis, is a common chronic, autoimmune inflammatory skin disea.
At present, most of the preferred topical treatment options for psoriasis are glucocorticoids and vitamin D derivativ.
Tapinarof is a "first-in-class" aryl hydrocarbon receptor modulat.
▲The molecular structure of Tapinarof (Image source: Edgar181, Public domain, via Wikimedia Commons)
▲The molecular structure of Tapinarof (Image source: Edgar181, Public domain, via Wikimedia Commons)Aromatic hydrocarbon receptors play an important role in regulating autoimmune respons.
In two pivotal Phase 3 clinical trials, tapinarof met all primary and secondary endpoin.
36% 6% 40% and 6%
In the long-term extension study, patients who achieved complete clearance of their skin symptoms maintained clear or near clear skin for an average of 4 months after drug discontinuatio.
Patients who achieved complete clearance of skin symptoms maintained clear or near clear skin for an average of 4 months after discontinuation
The 52-week long-term efficacy data showed that adult plaque psoriasis patients treated with tapinarof cream achieved durable improvements in efficacy outcomes and quality of life, with no treatment failur.
87% of patients believe that this therapy is more effective than previous topical therapy
"We are delighted that the FDA has approved Vta.
In addition to treating psoriasis, tapinarof is currently being tested in a Phase 3 clinical trial for atopic dermatitis, with top-line results expected in the first half of next ye.
Tapinarof is currently being tested in a Phase 3 clinical trial for the treatment of atopic dermatitis, with top-line results expected in the first half of next ye.
References:
[1] FDA Approves Dermavant's VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Yea.
[1] FDA Approves Dermavant's VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Yea.
[2] Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psorias.
Retrieved August 26, 2020, from https:// tapinarof-cream-in-adult-patients-with-plaque-psoriasis/
